Amgen: Stomach Neoplasms trials

The registry lists 14 Stomach Neoplasms studies with Amgen as lead sponsor. 0 are open to participants now and 2 have results posted.

Phase 1 6Phase 2 6Phase 3 4No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction CancerCompletedNCT03694522Phase 2Results posted
• Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced AnaemiaCompletedNCT01444456Results posted
• A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid TumorsCompletedNCT06131398Phase 1
• A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.TerminatedNCT05322577Phase 1/2
• Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Phase 3
• A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)Active, not recruitingNCT05094336Phase 1/2
• Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Phase 3
• Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic CancersTerminatedNCT04117958Phase 1
• A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric CancerTerminatedNCT02137343Phase 3
• A Phase 1/2 Study Evaluating AMG 337 in Asian SubjectsCompletedNCT02096666Phase 1/2
• Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid TumorsTerminatedNCT02016534Phase 2
• Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJCompletedNCT01791374Phase 1
• First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) AdenocarcinomaTerminatedNCT01697072Phase 3
• Study of T900607-Sodium in Subjects With Previously Treated Gastric Cancer or Adenocarcinoma of the EsophagusSuspendedNCT00048529Phase 2